NASDAQ | VICL: 2.43  +0.03
investors
Investors

Vical to Host Virtual Research & Development Day on May 2, 2017

04/24/2017


SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that it will host a virtual Research & Development Day for analysts, investors and media on Tuesday, May 2, 2017, beginning at 9:00 a.m. PT. This event will be available via webcast and conference call.

The event will provide a comprehensive overview of Vical’s product pipeline with an emphasis on the HSV-2 and invasive aspergillosis programs, including presentations by members of the Vical leadership team and two leading experts:

  • Anna Wald, MD, MPH, Professor, Department of Medicine, Epidemiology and Laboratory Medicine at the University of Washington and Lead Investigator in the ongoing Phase 2 trial of Vical’s HSV-2 therapeutic vaccine candidate
  • Haran Schlamm, MD, infectious disease specialist and former Senior Medical Director at Pfizer,  responsible for clinical development, medical and regulatory affairs for Pfizer’s antifungal portfolio

Listeners may access the accompanying slide presentation through the webcast at www.vical.com. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2239 (preferred), or (888) 455-2308 (toll-free), and reference confirmation code 9084195. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9084195. The call also will be available live and archived through the events page at www.vical.com. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at ir@vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact:
Tony Ramos
(858) 646-1127
Website:  www.vical.com

Primary Logo

Source: Vical Incorporated

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.